Yousif Capital Management LLC Sells 819 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Yousif Capital Management LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,295 shares of the medical research company’s stock after selling 819 shares during the quarter. Yousif Capital Management LLC’s holdings in IQVIA were worth $4,578,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of IQV. FMR LLC boosted its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA during the 3rd quarter valued at $147,683,000. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB lifted its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, KBC Group NV grew its holdings in IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after purchasing an additional 250,458 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on IQV shares. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, TD Cowen dropped their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Stock Performance

IQVIA stock opened at $208.13 on Friday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company’s 50-day moving average is $200.53 and its 200 day moving average is $219.80. The firm has a market capitalization of $37.78 billion, a P/E ratio of 27.31, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. Research analysts forecast that IQVIA Holdings Inc. will post 10.18 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.